Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Other Accumulated Expenses (2019 - 2025)

BioNexus Gene Lab's Other Accumulated Expenses history spans 7 years, with the latest figure at $59147.0 for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $59147.0 for Q4 2025, up 16.39% from a year ago — trailing twelve months through Dec 2025 was $59147.0 (up 16.39% YoY), and the annual figure for FY2025 was $59147.0, up 16.39%.
  • Other Accumulated Expenses for Q4 2025 was $59147.0 at BioNexus Gene Lab, up from $56803.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $59147.0 in Q4 2025 to a low of -$16793.0 in Q1 2021.
  • The 5-year median for Other Accumulated Expenses is $25537.0 (2021), against an average of $30367.7.
  • The sharpest move saw Other Accumulated Expenses surged 266.48% in 2021, then tumbled 36.54% in 2022.
  • Year by year, Other Accumulated Expenses stood at $18272.0 in 2021, then decreased by 9.32% to $16569.0 in 2022, then skyrocketed by 109.02% to $34632.0 in 2023, then soared by 46.73% to $50816.0 in 2024, then rose by 16.39% to $59147.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $59147.0, $56803.0, and $55809.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.